Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
OwnerConstantin Bona, Habib Zaghouaniinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to chimeric antibodies which comprise a B cell epitope, a T cell epitope, and/or an antigen binding site. The chimeric antibodies may be produced by replacing at least a portion of an immunoglobulin molecule with the desired epitope or antigen binding site such that the functional capabilities of the epitope and the parent immunoglobulin are retained. The chimeric antibodies of the invention may be used to enhance an immune response against pathogens and tumor cells in subjects in need of such treatment.
Claims6
A chimeric immunoglobulin molecule, wherein a CDR loop of a parent immunoglobulin molecule is deleted and replaced, in the chimeric immunoglobulin molecule, with a peptide comprising a T cell epitope, wherein a second CDR loop of the parent immunoglobulin, other than the CDR loop replaced by the T cell epitope, is deleted and replaced, in the chimeric immunoglobulin molecule, with a second peptide comprising a B cell epitope.
Dependencies are inferred from the claim text.